Inhibrx Biosciences (INBX) Net Cash Flow (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Net Cash Flow data on file, last reported at -$28.9 million in Q4 2025.

• Net Cash Flow for Q4 2025 came in at -$28.9 million, up 33.99% year-over-year; the trailing twelve-month figure through Dec 2025 was -$28.4 million (up 77.36% YoY), and the FY2025 annual result was -$28.4 million, up 77.36% from the prior year.
• Net Cash Flow improved to -$28.9 million in Q4 2025 per INBX's latest filing, from -$33.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $144.8 million in Q3 2023 and troughed at -$59.4 million in Q4 2023.
• A 3-year average of -$6.8 million and a median of -$29.4 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow plunged 121.08% in 2024, then soared 351.26% in 2025.
• A 3-year view of Net Cash Flow shows it stood at -$59.4 million in 2023, then climbed by 26.37% to -$43.7 million in 2024, then surged by 33.99% to -$28.9 million in 2025.
• Business Quant data shows INBX's Net Cash Flow at -$28.9 million in Q4 2025, -$33.5 million in Q3 2025, and -$30.0 million in Q2 2025.